CG Oncology, Inc. (CGON)

NASDAQ: CGON · Real-Time Price · USD
27.69
-0.49 (-1.74%)
May 6, 2025, 9:46 AM EDT - Market open
-1.74%
Market Cap 2.11B
Revenue (ttm) 1.14M
Net Income (ttm) -88.04M
Shares Out 76.22M
EPS (ttm) -1.41
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 75,450
Open 28.25
Previous Close 28.18
Day's Range 27.95 - 28.25
52-Week Range 14.80 - 40.47
Beta n/a
Analysts Strong Buy
Price Target 62.90 (+127.16%)
Earnings Date May 16, 2025

About CGON

CG Oncology, Inc., a late-stage clinical biopharmaceutical company, develops and commercializes backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003, which is in phase 3 clinical trial for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 that is in phase 2 clinical trial to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretost... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Jan 25, 2024
Employees 113
Stock Exchange NASDAQ
Ticker Symbol CGON
Full Company Profile

Financial Performance

In 2024, CG Oncology's revenue was $1.14 million, an increase of 458.33% compared to the previous year's $204,000. Losses were -$88.04 million, 29.9% more than in 2023.

Financial Statements

Analyst Forecast

According to 11 analysts, the average rating for CGON stock is "Strong Buy." The 12-month stock price forecast is $62.9, which is an increase of 127.16% from the latest price.

Price Target
$62.9
(127.16% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

CG Oncology's Bladder Cancer Drug Impresses Investors - Here's Why

75.5% complete response rate reported in BOND-003 Cohort C study for high-risk NMIBC patients unresponsive to BCG.

7 days ago - Benzinga

CG Oncology Announces Best-in-Disease Durability Data in BOND-003 Cohort C and Promising Early Signal in Cohort P for Cretostimogene Grenadenorepvec at the American Urological Association Annual Meeting

CG Oncology Announces Best-in-Disease Durability Data in BOND-003 Cohort C and Promising Early Signal in Cohort P for Cretostimogene Grenadenorepvec at AUA

9 days ago - GlobeNewsWire

CG Oncology Looks Attractive At Current Prices (Rating Upgrade)

CG Oncology, Inc.'s lead asset, cretostimogene grenadenorepvec, shows promising efficacy in bladder cancer with competitive complete response rates in clinical trials. Recent data updates reveal a 74....

4 weeks ago - Seeking Alpha

Cretostimogene Grenadenorepvec Data Continues to Demonstrate Best-in-Class Durability of Response as well as Consistent and Compelling Safety and Efficacy

Cretostimogene Grenadenorepvec Data Continues to Demonstrate Best-in-Class Durability of Response as well as Consistent and Compelling Safety and Efficacy

6 weeks ago - GlobeNewsWire

CG Oncology to Present at the TD Cowen 45th Annual Health Care Conference

IRVINE, Calif., Feb. 26, 2025 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladd...

2 months ago - GlobeNewsWire

CG Oncology Announces Closing of Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

IRVINE, Calif., Dec. 16, 2024 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (Nasdaq: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladd...

5 months ago - GlobeNewsWire

CG Oncology: Positive Phase 3 Outcome Could Lead To BLA Of Cretostimogene

CG Oncology, Inc. reported positive phase 3 BOND-003 results for Cretostimogene in treating BCG-unresponsive NMIBC, presented at the SUO 25th Annual Meeting. The company aims to use Cretostimogene as ...

5 months ago - Seeking Alpha

CG Oncology Announces Pricing of Public Offering

IRVINE, Calif., Dec. 12, 2024 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (Nasdaq: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladd...

5 months ago - GlobeNewsWire

CG Oncology Announces Proposed Public Offering

IRVINE, Calif., Dec. 11, 2024 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (Nasdaq: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladd...

5 months ago - GlobeNewsWire

Health Rounds: Experimental CG Oncology immunotherapy shows promise in bladder cancer

An experimental immunotherapy drug is a potentially effective treatment for patients with bladder cancer who no longer respond to current therapies, researchers reported on Thursday at the Society of ...

5 months ago - Reuters

Groundbreaking Cretostimogene Grenadenorepvec Monotherapy Data Demonstrates Sustained, Durable Complete Responses in High-Risk BCG-Unresponsive Non-Muscle Invasive Bladder Cancer

Groundbreaking Cretostimogene Grenadenorepvec Monotherapy Data Demonstrates Sustained, Durable Complete Responses in High-Risk BCG-Unresponsive Non-Muscle

5 months ago - GlobeNewsWire

CG Oncology to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference

IRVINE, Calif., Aug. 30, 2024 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladd...

8 months ago - GlobeNewsWire

CG Oncology: Promising Data, But Looks Expensive

CG Oncology's bladder cancer molecule, cretostimogene, showed high success with a 75.2% complete response rate in a phase 3 monotherapy study. Cretostimogene, an oncolytic immunotherapy, works by sele...

9 months ago - Seeking Alpha

CG Oncology Reports Second Quarter 2024 Financial Results and Provides Business Updates

– Final positive safety and efficacy findings from CORE-001 study of Cretostimogene Grenadenorepvec in combination with Pembrolizumab in BCG-Unresponsive NMIBC simultaneously published online by Natur...

9 months ago - GlobeNewsWire

CG Oncology Bringing Undervalued Innovation To Bladder Cancer

CG Oncology's cretostimogene shows high potential to disrupt the NMIBC market with promising efficacy and safety data. The company is initially targeting high-risk NMIBC patients who no longer respond...

10 months ago - Seeking Alpha

CG Oncology Announces Nature Medicine Publication of Final Results from CORE-001 Study of Cretostimogene Grenadenorepvec in Combination with Pembrolizumab in BCG-Unresponsive NMIBC

CG Oncology Announces Nature Medicine Publication of Final Results from CORE-001 Study of Cretostimogene Grenadenorepvec in Combination with Pembrolizumab

11 months ago - GlobeNewsWire

CG Oncology to Present Positive Final Results from Phase 2 CORE-001 Study of Cretostimogene Grenadenorepvec in Combination with Pembrolizumab in BCG-Unresponsive High-Risk NMIBC at ASCO 2024 Annual Meeting

IRVINE, Calif., May 24, 2024 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladde...

1 year ago - GlobeNewsWire

CG Oncology Reports First Quarter 2024 Financial Results and Provides Business Updates

Cretostimogene Monotherapy Demonstrated 75.2% Complete Response (CR) Rate at Any Time in Bacillus Calmette Guerin (BCG)-Unresponsive, High-Risk Non-Muscle Invasive Bladder Cancer (HR-NMIBC) First Pati...

1 year ago - GlobeNewsWire

CG Oncology: ASCO Play And Top-Line Data End Of 2024 Could Drive Further Value

CG Oncology, Inc. achieved positive results from its phase 3 BOND-003 study using cretostimogene for the treatment of high-risk BCG unresponsive NMIBC patients; Final data expected end of 2024.

1 year ago - Seeking Alpha

Cretostimogene Monotherapy Demonstrated 75.2% Complete Response Rate in High-Risk, BCG-Unresponsive Non-Muscle Invasive Bladder Cancer

- Phase 3 BOND-003 study results showed sustained, durable complete responses over 12 months with novel investigational oncolytic immunotherapy - - Company will hold an investor conference call today ...

1 year ago - GlobeNewsWire

CG Oncology to Host Virtual Investor Event on Friday, May 3, 2024

IRVINE, Calif., April 26, 2024 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone blad...

1 year ago - GlobeNewsWire

CG Oncology to Unveil Encouraging Results on Cretostimogene in Combination with Pembrolizumab at ASCO 2024

IRVINE, Calif., April 24, 2024 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone blad...

1 year ago - GlobeNewsWire

CG Oncology to Present Results on Cretostimogene at the AUA 2024 Annual Meeting

- New 12-month data from the Phase 3 BOND-003 trial to be featured in an oral presentation in the Paradigm-shifting, Practice-changing Clinical Trials in Urology plenary session - - New 12-month data ...

1 year ago - GlobeNewsWire

Protara: A Bombed Out Biotech With A Very Positive Skew

Protara Therapeutics is developing therapies for cancer and rare diseases, with a focus on non-muscle invasive bladder cancer and lymphangiomas.

Other symbols: TARA
1 year ago - Seeking Alpha